CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib

PURPOSE: Although MET exon 14 (METex14)–altered lung cancers were first identified more than a decade and a half ago, the frequency of CNS metastatic disease remains poorly defined. Furthermore, the seminal trial of crizotinib in these patients (PROFILE 1001) did not report patterns of CNS response...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCO Precis Oncol
Auteurs principaux: Offin, Michael, Luo, Jia, Guo, Robin, Lyo, John K., Falcon, Christina, Dienstag, Jordan, Wilkins, Olivia, Chang, Jason, Rudin, Charles M., Riely, Gregory, Rekhtman, Natasha, Arcila, Maria E., Heller, Glenn, Ladanyi, Marc, Li, Bob T., Kris, Mark G., Paik, Paul, Drilon, Alexander
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
Original Reports
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446485/
https://ncbi.nlm.nih.gov/pubmed/32923895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00098
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires